Pumitamig + Chemotherapy vs. Bevacizumab + Chemotherapy in patients with previously untreated metastatic colon cancer

A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Disease Types: Colon

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer 

For More Information:

https://clinicaltrials.gov/study/NCT07221357?term=NCT07221357&rank=1